News | May 18, 2025
Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
EBITDA before special items decreases to €4.08 billion (7.4%)
The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices
Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
ekincare has raised a total funding of $22M since 2015 till date
Investment demonstrates confidence in America’s commitment to science and innovation
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Subscribe To Our Newsletter & Stay Updated
